From the mid-February in Orlando, Florida, USA, the 2006 International Custom Chemicals Exhibition presented such information: Some well-known companies in Europe and America are pushing the application of biotechnology in the field of custom synthesis in order to achieve rapid growth in this high technology. The industry has developed steadily to avoid head-on confrontations with emerging Asian competitors.
At this exhibition organized by the American Synthetic Organic Chemical Manufacturers Association, the results released by chemical companies are mostly related to the topic of biocatalysis. DSM Medical Chemicals stated that it is currently working with IEP, a German biocatalysis technology company, to develop biocatalytic technology routes that can replace traditional chemical synthesis processes. In the next step, the IEP will screen relevant biocatalysts according to the intended target. After that, DSM will organize the scaled-up experiments of selected biocatalytic routes. Finally, these new biotechnological methods will be used to produce active pharmaceutical ingredients and intermediates. body.
PCAS, a French fine chemicals supplier, said it has partnered with a biotechnology company to form PCAS Biochemicals. The joint venture will integrate the intellectual property rights of both parties and introduce chemical biocatalysis routes to synthesize active pharmaceutical ingredients and intermediates.
BASF and Degussa also intend to use their proprietary technologies in the field of biocatalysis to provide customers with better services. BASF said that the company has applied biocatalytic processes to produce some chiral compounds. In the next step, the company will also provide customers with services including biocatalyst screening, optimization, process amplification and commercial production. According to reports, BASF has announced an alliance with Diversa, a biotechnology company, to jointly promote the research and development of biological enzymes.
Degussa is naturally not far behind in this regard, it has set up a biocatalytic service center. The center mainly provides customers with a variety of industrial biotransformation programs, including screening and optimization of bacterial strains for the biocatalytic process, process design, and tissue trial production. On the other hand, Degussa is also working to reduce the cost of research and development and production. At this exhibition, it announced that it has established a long-term production cooperation relationship with the Indian fine chemicals company Hikal. Both parties will make full use of Degussa's patented technology and Hikal's low-cost advantages in advanced intermediates and active pharmaceutical ingredients. Cooperative production in the field.
Reaxa, which was established for a short time, was a joint venture formed by Avecia and the University of Cambridge a year ago. It is mainly engaged in the development of catalyst packaging technology. Reaxa CEO announced that it will invest $6 million to establish Reaxa Biotech. The new company will focus on the development of polymer drug synthesis, solid-phase synthesis technology, and polymer controlled release technology.
At the exhibition, there were two news about Indian companies' mergers and acquisitions that shocked the industry. First, India’s Nicholas Piramal acquired Avizia Pharmaceuticals, and Avizia Pharmaceuticals’ head of custom chemical business said that the company’s The goal is to become one of the top three in the global customized services market. Second, Shasun Chemicals & Drugs of India will acquire Rhodia's custom chemical division.
Non-Standard Automation Equipment
Non-Standard Automation Equipment,Automatic Winding Machine,Brand Fully Automated Manipulator,Face Mask Ear Strap Machine
RFC PRECISION MACHINE LIMITED , https://www.rfc-sz.com